Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytochrome P450dbl phenotypes in malignant and benign breast disease.

European journal of cancer (Oxford, England : 1990) - 1 Jan 1990

Pontin J E, Hamed H, Fentiman I S, Idle J R

Abstract excerpt

129 female patients with breast cancer and 79 controls undergoing biopsy for benign breast conditions had debrisoquine hydroxylator phenotype established. 129 female hospital patients with known hydroxylator phenotype were used as another control group. The breast cancer cases differed significan...

Topics

Adult
Breast Diseases
Breast Neoplasms
Cytochrome P-450 CYP2D6
Cytochrome P-450 Enzyme System
Debrisoquin
Female
Genetic Markers
Humans
Middle Aged
Mixed Function Oxygenases
Phenotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 2145896
DOI: 10.1016/0277-5379(90)90153-k

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-2145896-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytochrome P450dbl phenotypes in malignant and benign breast disease.PMID 2145896Read ↗

Debrisoquine hydroxylase (CYP2D6) and prostate cancer.Semantic proximity Read ↗

Debrisoquine metabolism and lung cancer risk.Semantic proximity Read ↗

The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.Semantic proximity Read ↗

A protocol for the safe administration of debrisoquine in biochemical epidemiologic research protocols for hospitalized patients.Semantic proximity Read ↗

Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.Semantic proximity Read ↗

Debrisoquin oxidation genotype and susceptibility to lung cancer.Semantic proximity Read ↗

Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.Semantic proximity Read ↗

Frequency of the variant allele CYP2D6(C) among North American Caucasian lung cancer patients and controls.Semantic proximity Read ↗

Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.Semantic proximity Read ↗

Lung tumor resection does not affect debrisoquine metabolism.Semantic proximity Read ↗

New opportunities in cancer risk evaluation using PCR-based DNA analysis for CYP2D6.Semantic proximity Read ↗

Lung cancer and the debrisoquine metabolic phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.